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Abstract
Background: The p75 neurotrophin receptor (p75NTR) is a cancer stem cell (CSC) marker in esophageal squamous cell
carcinoma (ESCC). This study aimed to assess the use of p75NTR in detecting circulating tumor cells (CTCs) in ESCC.
Methods: Peripheral blood mononuclear cell expression of epithelial cell adhesion molecule (EpCAM) and p75NTR
was detected in 23 ESCC patients (13 received chemo- or chemoradiotherapy and 10 received curative surgery) and
10 healthy controls by flow cytometry.
Results: EpCAM + p75NTR+ cell counts (average ± SD) were significantly higher in patients (n = 23, 16.0 ± 18.3)
compared to controls (n = 10, 0.4 ± 0.9, p = 0.013). The sensitivity and specificity to differentiate ESCC patients from
controls were 78.3 and 100 % (cut-off value 4.0), respectively. EpCAM + p75NTR+, but not EpCAM+ p75NTR− cell
counts, correlated with clinically diagnosed distant metastasis (n = 13, p = 0.006) and pathological venous invasion in
resected primary tumors (n = 10, p = 0.016). Malignant cytology was microscopically confirmed in isolated EpCAM+
p75NTR+ cells with immunocytochemical double staining.
Conclusions: p75NTR is suggested to be a useful marker for clinically significant CTCs, which exhibit highly metastatic
features in ESCC.
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Background
Esophageal squamous cell carcinoma (ESCC) is a leading
cause of cancer-related deaths worldwide [1]. Despite
advances in its diagnosis and multimodal therapies, the
prognosis for ESCC patients remains poor with post-
operative 5-year survival rates of 42 %, due to high inci-
dences of metastasis [2, 3].
Lately, attention has focused on the proportion of
circulating tumor cells (CTCs) as an early marker of
metastasis [4]. The CTC detection method most exten-
sively used is based on immunomagnetic enrichment
with epithelial cell adhesion molecule (EpCAM) and
cytokeratin antibodies for subsequent immunological
identification [5, 6]. Quantification of CTCs using this
method has established CTCs as an independent
prognostic factor in patients with advanced colorectal
[7], breast [8], and prostate cancer [9].
Other studies have identified cancer stem cells (CSCs),
which are defined as a small fraction of tumor cells
capable of self-renewal, tumorigenicity, and drug resist-
ance [10, 11]. CSCs are also responsible for metastasis
through processes such as epithelial mesenchymal
transition, invasion into vessels, circulation, and tumor
initiation [12, 13].
Moreover, reports suggest that a percentage of CTCs
have characteristics reminiscent of CSCs, which are
termed circulating tumor stem cells (CTSCs) [14]. Com-
pared to CTCs, CTSCs are potentially a more accurate
prognostic factor since cancer growth is dependent on
CSCs [15].
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In ESCC, several cell surface antigens have been
reported to be CSC markers, such as p75 neurotrophin
receptor (p75NTR) [16–18] and CD44 [19]. A recent re-
port demonstrated that p75NTR-positive cells in ESCC
cell lines showed significantly higher colony formation,
enhanced tumor formation in mice, and greater che-
moresistance, along with stronger expression of epithe-
lial mesenchymal transition (EMT)-related genes [18].
However, detection of CTCs using CSC markers in
ESCC has not previously been reported. The aim of this
study was to detect CTCs in the peripheral blood of
ESCC patients using combined expression of EpCAM,
CD44, and p75NTR to assess its clinical significance.
Methods
Patients
This study included a series of 23 primary ESCC patients
who consulted our hospital between January and
December 2014. Nineteen of 23 patients were men, and
the median age was 62.3 (range 38–88) years. Ten
patients underwent R0 resection, while 13 patients
received chemotherapy (CT) or chemoradiation therapy
(CRT) without resection. Clinicopathological classifica-
tions were determined according to the criteria of the
Union for International Cancer Control (UICC)-TNM
Classification of Malignant Tumors Staging System
(seventh edition). In the patients who underwent CT or
CRT, 1, 4, 2, 1, and 5 patients were clinically diagnosed
as cStageIB, cStageIIIA, cStageIIIB, cStageIIIC, and
cStageIV (intramural metastasis to the stomach 3; bone
1; distant lymph node 1), respectively. In the patients
who underwent surgery, 2, 5, 2, and 1 patients were
pathologically diagnosed as stage IA, stage IIA, stage
IIIA, and stage IV (T3N2M1: intramural metastasis to
the stomach), respectively. Three patients presented with
lymph node metastasis and lymph vessel invasion, and
three presented with venous invasion.
Ten healthy volunteers were also recruited as negative
controls. Subjects provided informed written consent
prior to commencing the study, and all were enrolled
following Institutional Review Board approval (no. 20-75).
Immunohistochemistry
Formalin fixed-paraffin embedded sections were pre-
pared for examination. Antibodies required for immuno-
histochemical analysis included anti-cytokeratin OSCAR
IVD (dilution 1:200) and anti-human p75NTR monoclo-
nal antibody (NGFR5; dilution 1:100) (Abcam Ltd.,
Cambridge, UK). Immunostaining was performed using
Envision Plus kits/HRP/DAB (Dako Cytomation, Kyoto,
Japan), as recommended by the supplier. Counterstain-
ing was performed using Mayer’s hematoxylin (Dako
Cytomation, Kyoto, Japan).
Peripheral blood sample processing and analysis
Blood samples were collected from ten patients who
underwent R0 resections on the day before surgery. As
for the 13 patients who received CT or CRT, blood sam-
ples were obtained before the start of the therapy. Blood
samples were collected from each donor in ethylene-
diamine-tetra-acetic acid (EDTA)-2K Vacutainer Tubes
(TERUMO, Tokyo, Japan). Specimens were maintained
at 4 °C and processed within 4 h of phlebotomy.
Mononuclear cells were enriched from 3 mL of per-
ipheral blood using LymphoPrep™ (Nycomed AS,
Oslo, Norway). These were incubated in the presence
of allophycocyanin (APC)-conjugated monoclonal
mouse anti-human EpCAM [clone HEA (human epithelial
antigen)-125, dilution 1:100], fluorescein isothiocyanate
(FITC)-conjugated monoclonal mouse anti-human p75
neurotrophic receptor (p75NTR, clone ME20.4-1.H4,
dilution 1:50), FITC-conjugated monoclonal mouse anti-
human CD44 (clone BD105, dilution 1:100, Miltenyi
Biotec), or isotype-matched APC/FITC-conjugated
antibodies (clone IS5-21F5, dilution 1:50) (Miltenyi Biotec,
Bergisch Gladbach, Germany) at 4 °C for 30 min. Samples
were analyzed on the fluorescence-activated cell sorting
(FACS)Canto II flow cytometer and sorted on a FACS
Aria II flow cytometer using BD FACS Diva software (BD
Biosciences, San Jose, CA, USA). Cells were stained with
7-aminoactinomycin D (7-AAD; Bio-Rad Laboratories,
CA, USA) to exclude any dead cells.
Flow cytometric detection of cultured cells mixed with
blood samples
Human ESCC cell lines (KYSE30 and KYSE140) were
established by Shimada and colleagues and cultured in
Ham’s F12/RPMI-1640 (Wako, Osaka, Japan) with 2 %
fetal calf serum (Gibco; Grad Island, NY, USA) according
to a previously published method [20]. For the accuracy
assay, 0, 10, 100, and 500 of KYSE cells were mixed with
3 mL each of peripheral blood samples obtained from the
healthy volunteers.
Cytological examination of the sorted cells
Sorted EpCAM+ p75NTR+ cells were centrifuged at
250× g for 5 min using a Cytospin™ chamber (Stat Spin,
Beckman Coulter, Tokyo, Japan) and evaluated using a
transmitted light microscope (BX61/DP70, Olympus,
Tokyo, Japan).
Culture of the sorted cells
Sorted EpCAM+ p75NTR+ cells were resuspended with
100 μl of Ham’s F12/RPMI-1640 with 2 % fetal calf
serum and seeded onto one of the 96-well cell culture
plates and cultured at 37 °C in a humidified atmosphere
of 5 % carbon dioxide in air for 14 days.
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Statistical analysis
Statistical analyses were performed using JMP v.11 (SAS
Institute Inc., Cary, NC, USA). Chi-square and Fisher’s
exact tests were performed, and probability (p) values of
less than 0.05 were deemed statistically significant.
Receiver operating characteristic (ROC) curves and the
area under the curve (AUC) were used to assess the feasi-
bility of using EpCAM+ cells and EpCAM+/p75NTR+
cell counts as a measure of CTC numbers in patients with
ESCC.
Results
Accuracy assay for detecting CTCs
EpCAM expression was detected in 100 and 100 % of
KYSE30 and KYSE140, respectively. Within the EpCAM+
cells, 14.6 and 35.5 % of KYSE30 and KYSE140 cells,
respectively, were p75NTR+ (Fig. 1a). EpCAM+ cells were
detected in the peripheral blood of healthy volunteers, in
which 0, 10, 100, and 500 of KYSE30 and KYSE140 cells
were mixed beforehand (Fig. 1b). Regression analysis on




Fig. 1 a KYSE30 and KYSE140 cells co-stained with anti-EpCAM-APC and anti-p75NTR-FITC were analyzed by two-color flow cytometry. Data of
percentages of cells in each quadrant are shown. b Mononuclear cells from 3 mL peripheral blood from a healthy control, in which 100 of KYSE30
and KYSE140 cells were mixed and co-stained with anti-EpCAM-APC and anti-p75NTR-FITC, were analyzed by two-color flow cytometry. c Representative
result of the number of spiked KYSE30 and KYSE140 cells plotted against the observed number of cells using flow cytometry is shown
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KYSE30 and KYSE140 cells produced a slope of 0.71
(95 % confidence interval (CI) 0.68–0.74) and 0.70 (95 %
CI 0.67–0.74), respectively. The intercepts were 4.8 (95 %
CI −4.4–14.0) and 1.4 (95 % CI −4.6–7.4) with the correl-
ation coefficients (R2) of 0.997 and 0.988, respectively
(Fig. 1c).
Detection of CTCs in ESCC patients based on EpCAM
expression
EpCAM+ cells were detected in 5 of 10 (50.0 %) healthy
controls and 22 of 23 (95.7 %) ESCC patients with cell
counts (average ± SD) of 2.3 ± 2.5 and 34.0 ± 35.8, re-
spectively (p = 0.011, Fig. 2). Based on the ROC curve
analysis to differentiate ESCC patients from controls, the
largest AUC value for EpCAM+ cell counts was 7.0 with
optimal sensitivity and specificity measurements of 86.9
and 100 %, respectively.
Detection of CTCs in ESCC patients based on p75NTR
expression
EpCAM+ p75NTR+ cells were detected using two-color
flow cytometry (Fig. 3a) in 2 of the 10 (20 %) controls
and 20 of 23 (86.9 %) ESCC patients, with cell counts
(average ± SD) of 0.4 ± 0.9 and 16.0 ± 18.3, respectively
(p = 0.013, Fig. 3b).
The proportion of EpCAM+ p75NTR+ cells in
EpCAM+ cells (average ± SD) was 56.7 ± 39.6 % (range
5.6–100.0 %). Based on the ROC curve analysis to differ-
entiate ESCC patients from controls, the largest AUC
value for EpCAM+ p75NTR+ cell counts was 4.0 with
optimal sensitivity and specificity measurements of 78.3
and 100 %, respectively. The relationship between CTC
counts and various clinicopathological features in the 13
patients who underwent CT or CRT is presented in
Table 1. The mean EpCAM+ p75NTR+ cell counts
correlated with clinically diagnosed distant metastasis
(p = 0.003), while EpCAM + p75NTR− cell counts did
not show relationship with any of these pathological
factors. The relationships between CTC counts and vari-
ous clinicopathological factors in the ten patients who
underwent R0 resection are presented in Table 2. The
mean EpCAM+ p75NTR+ cell counts correlated with
pathological venous invasion (p = 0.016), while EpCAM+
p75NTR− cell counts did not show relationship with any
of the pathological factors.
Detection of CTCs in ESCC patients based on CD44
expression
EpCAM+CD44+ cells were detected in 5 of 10 (50.0 %)
healthy controls and 22 of 23 (95.7 %) ESCC patients
with cell counts (average ± SD) of 1.5 ± 1.7 and 33.6 ±
35.6, respectively (p = 0.001, Fig. 3c, d). The proportion of
EpCAM+CD44+ cells in EpCAM+ cells (average ± SD)
was 98.6 ± 3.1 % (range 90.5–100 %), indicating that al-
most all the EpCAM+ cells were CD44+ and thus it was
not useful to differentiate subpopulations in EpCAM+
CTCs.
Cytology of sorted EpCAM + p75NTR+ cells
We evaluated sorted EpCAM+ p75NTR+ cells from the
peripheral blood of an ESCC patient microscopically. A
representative figure of cells staining positive for
EpCAM-APC (red) and p75NTR-FITC (green), in the
cell membranes, is provided in Fig. 4. The cell repre-
sented is a mononuclear cell, 35 μm in diameter with a
high nucleocytoplasmic ratio, which led cytopathologists
to establish a diagnosis of malignant cytology.
We could not establish primary culture of the
EpCAM+ p75NTR+ cells sorted from any of the 23
examined patients (data not shown).
Expression of p75NTR in the primary tumor of resected
ESCC specimens
The expression of p75NTR was detected in five (50.0 %)
tumors, in which the first few layers nearest to the
tumor’s infiltrative margin exhibited positive staining
(Fig. 5). There was no relationship between p75NTR
Fig. 2 Mean numbers of EpCAM+ cells from 3 mL peripheral blood
of ESCC patients and controls. Error bars represent the standard error
of the mean
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expressions in primary tumors versus EpCAM+ cells of
the peripheral blood.
Discussion
In this study, we detected CTCs by flow cytometry based
on the combined expression of EpCAM and p75NTR in
patients with ESCC. Our results demonstrated that the
EpCAM+ cell count in the peripheral blood of patients
was significantly higher than that of controls, reflecting
a tumor-bearing state, and thus indicating successful
detection of CTCs using this method. Our results were
consistent with those in previously published reports of
patients with metastatic lung cancer (CK + CD45− CTCs
detected by flow cytometry in all examined patients, with
significantly higher cell counts than controls) [21, 22]. We
revealed that detecting a combination of EpCAM and
p75NTR expression was more accurate as a diagnostic
marker than EpCAM detection alone.
In addition, our results highlighted that EpCAM+
p75NTR+, but not EpCAM+ p75NTR− CTC counts,
A B
C D
Fig. 3 a Mononuclear cells from 3 mL peripheral blood were co-stained with anti-EpCAM-APC and anti-p75NTR-FITC and analyzed by two-color
flow cytometry. Quadrant markers were set according to isotype-matched controls. b Mean numbers of p75NTR+ CTCs from 3 mL peripheral
blood of ESCC patients and controls. Error bars represent the standard error of the mean. c Mononuclear cells from 3 mL peripheral blood were
co-stained with anti-EpCAM-APC and anti-CD44-FITC and analyzed by two-color flow cytometry. Quadrant markers were set according to isotype-
matched controls. d Mean numbers of CD44+ CTCs from 3 mL peripheral blood of ESCC patients and controls. Error bars represent the standard
error of the mean
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correlated with clinically diagnosed distant metastasis
and pathological venous factors in the resected primary
tumor, demonstrating the highly invasive and metastatic
potential of CTCs with p75NTR expression.
Recent reports have identified CTSCs, which have
CSC-like potential and enhanced metastatic capacity in
various solid tumors, such as breast [23], colon [24], and
hepatocellular carcinoma [25], using a combination of
EpCAM and CSC markers in the each tumor (e.g., CD44
or CD133). Further reports have also demonstrated
CTSCs to be useful markers for the diagnosis, treatment
responsiveness, and prognosis of patients with breast
[26] and gastric cancer [27]. To the best of our know-
ledge, this is the first report to detect CTCs expressing a
CSC marker in ESCC patients using flow cytometry.
In this study, we also detected CTCs with combined
expression of EpCAM and CD44, which is one of the
other proposed CSC markers in ESCC [19]; however,
almost all the EpCAM+ cells were CD44+, indicating
that CD44 is almost equivalent to EpCAM as a CTC
marker and therefore it is not useful to differentiate sub-
populations of CTCs in ESCC.
The most widely studied CTC detection method is an
immunomagnetic-based enrichment, requiring fixation
of the cells, using EpCAM and cytokeratin antibodies
for subsequent immunological identification [5, 6].
Previous studies on the detection of CTCs in ESCC have
also used a CELLSEARCH system, which allows immu-
nomagnetic capture of fixed EpCAM+ cells in combin-
ation with cytokeratin and CD45 immunofluorescence
staining [28, 29]. In contrast, we used flow cytometry to
detect CTCs, which enabled us to analyze the expression
of multiple cell surface markers in viable cells. We
sorted an EpCAM+ p75NTR+ CTC and cytologically
identified an atypical cell as well.
However, we could not obtain primary culture of
sorted EpCAM+ p75NTR+ CTC from any of the 23 ex-
amined patients and thus could not assess the biological
properties of the cells. A recent report from our labora-
tory demonstrated that 100 and 3000 cells were minim-
ally required to establish colonies in vitro and mouse
xenograft tumors, respectively, using p75NTR+ cells
isolated from cultured KYSEs by flow cytometric cell
sorting, suggesting decreased cell survival and recovery
due to cell damage during isolation procedure [18].
Another possibility is that a small part (1/3000–1/100)
of p75NTR+ cells are true CSCs which can establish
colonies or xenograft tumors. In addition, a previous
report demonstrated that even using resected primary
tumor, only 21 esophageal cancer cell lines (KYSEs) were
Table 1 Relationship between the clinical features and mean EpCAM + p75NTR+ or EpCAM + p75NTR− CTC counts in patients who
received chemotherapy or chemoradiotherapy
Characteristics Number EpCAM + p75NTR+ (average ± SD) p value EpCAM + p75NTR− (average ± SD) p value
Male/female 9/4 16.4 ± 19.7/14.0 ± 14.4 0.764 26.0 ± 34.9/13.3 ± 14.1 0.504
Age ≥65/>65 5/8 22.8 ± 11.6/11.3 ± 11.9 0.114 38.2 ± 44.0/12.06 ± 11.7 0.131
Ce-Ut/Mt-Ae 2/11 19.0 ± 20.5/15.0 ± 12.2 0.666 2.0 ± 2.8/25.7 ± 31.4 0.325
T 0–2/3–4 1/12 7.0/16.4 ± 13.0 0.501 0/23.9 ± 30.6 0.468
N 0/1–3 1/12 7.0/16.4 ± 13.0 0.501 0/23.9 ± 30.6 0.468
M 0/1 8/5 7.1 ± 5.9/29.4 ± 6.4 *0.003 19.5 ± 20.8/26.2 ± 43.7 0.713
Stages 1–2/3–4 1/12 7.0/16.4 ± 13.0 0.501 0/23.9 ± 30.6 0.468
CTC circulating tumor cell, SD standard deviation
*p < 0.05
Table 2 Relationship between the clinicopathological features and mean EpCAM + p75NTR+ or EpCAM + p75NTR− CTC counts in
patients who underwent surgery
Characteristics Number EpCAM + p75NTR+ (average ± SD) p value EpCAM + p75NTR− (average ± SD) p value
Male/female 10/0 16.5 ± 25.2/– – 12.0 ± 31.9/– –
Age ≥65/>65 5/5 19.6 ± 11.9/13.4 ± 11.9 0.722 20.4 ± 45.6/23.6 ± 5.4 0.437
Ce-Ut/Mt-Ae 1/9 8.0/17.4 ± 26.6 0.745 0/13.3 ± 33.5 0.716
pT 0–2/3–4 4/6 2.0 ± 2.8/26.2 ± 29.3 0.146 27.0 ± 50.1/2.0 ± 4.9 0.246
pN 0/1–3 7/3 14.9 ± 27.7/20.3 ± 23.1 0.773 0.8 ± 2.3/38.0 ± 55.7 0.090
ly 0/1–2 7/3 14.9 ± 27.7/20.3 ± 23.1 0.773 0.8 ± 2.3/38.0 ± 55.7 0.090
v 0/1–2 7/3 5.0 ± 4.2/43.3 ± 35.6 *0.016 0.8 ± 2.3/38.0 ± 55.7 0.090
pStages 1–2/3–4 7/3 15.7 ± 27.2/18.3 ± 25.1 0.891 15.4 ± 38.2/4.0 ± 6.9 0.632
CTC circulating tumor cell, ly lymphatic invasion, v venous invasion, SD standard deviation
*p < 0.05
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established from 50 ESCC patients with a success rate of
42 % in the same culture condition which we used in
this study [20]. Taken together, improvement of devices,
procedure, and culture condition, which can enrich and
recover target cells without causing cell damage or cell
death, is needed to establish CTC isolation with higher
yield and higher viability. Thereafter, characterization of
the isolated EpCAM+ p75NTR+ CTCs may provide us
with a better understanding of their biological features
in ESCC.
A proportion of EpCAM+ cells was detectable, even in
controls, although the cell counts were significantly lower
than in ESCC patients. The presence of these cells could
possibly be explained by a nonspecific immunological
reaction or contamination of skin cells [30]. In addition, a
previous study in mice demonstrated the presence of
EpCAM+ bone marrow-derived mesenchymal stem cells
with expression of epithelial phenotypic markers [31],
suggesting that detection of EpCAM+ non-cancer cells is
possible in the peripheral blood. Again, characterization of
isolated EpCAM+ cells from the peripheral blood of
healthy controls may also provide us with a better under-
standing of the biological significance of EpCAM+ cells.
The presence of EpCAM+ p75NTR+ CTCs did not
correlate with p75NTR expression in the primary ESCC
tumors, demonstrating the heterogeneity of cell surface
marker expression, as has been shown in various other
types of tumors [32]. In addition, regulation of p75NTR
expression by various environmental stimuli, including
tissue injury and pro-inflammatory cytokines, has been
reported [33]. This may suggest possible induction of
p75NTR expression after mobilization of the metastatic
cancer cells into systemic circulation.
Conclusions
Our flow cytometric detection of CTCs in patients with
ESCC has highlighted the clinical significance of EpCAM
+ p75NTR+ CTCs in ESCC, providing us with a basis
from which to establish large-scale prospective studies.
Further investigations based on the isolation of viable
EpCAM+ p75NTR+ CTCs may shed light on the molecu-
lar and biological roles of these cells in tumor metastasis




p75NTR: p75 neurotrophin receptor; CSCs: cancer stem cells; ESCC: esophageal
squamous cell carcinoma; CTCs: circulating tumor cells; CTSCs: circulating tumor
stem cells; EpCAM: epithelial cell adhesion molecule.
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Fig. 4 Representative EpCAM+ and p75NTR+ cell sorted from 3 mL
peripheral blood in a patient with esophageal cancer using the
fluorescence-activated cell sorting (FACS) Aria II flow cytometer. The
images show an overlay of DAPI (blue), p75NTR (green), and EpCAM (red)
Fig. 5 Representative findings of immunohistochemical analysis of
p75NTR expression in resected ESCC tissue specimens
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